The role of antibody-drug conjugates in the treatment of lung cancerZlatanova, Tanya (Avtor) Changalova, Aynura (Avtor) Janžič, Urška (Avtor) ADCantibody-drug conjugatenon-small cell lung cancersmall-cell lung cancertargeted therapyimmunotherapyOver the last decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges.Frontiers Editorial Office, 2011-20262026-02-05 12:09:18Neznano27400UDK: 616.24-006:615.277ISSN pri članku: 2234-943XDOI: 10.3389/fonc.2026.1757564COBISS_ID: 267418115Frontiers in oncologysl© 2026 Zlatanova, Changalova and Janzic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.